Trial Profile

Evaluation of T-cell receptor clonality and the frequency/activation of immune populations for predicting response and elucidating the biology of anti-tumor immunity in stage 3 Non small cell lung cancer treated with Durvalumab

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
21 May 2021 Results (n=79) presented at the 112th Annual Meeting of the American Association for Cancer Research
31 Jan 2021 Results assessing evolution of T cell receptor clonality on chemoradiation and durvalumab and its correlation with survival (n=73) presented at the 2020 World Conference on Lung Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com